Statement of Unaudited Financial Result for the quarter ended on 30th September, 2025 alongwith Limited Review Report.

EBITDA margin compressionRevenue declinedNegative operating cash flowRelated-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.4%Reaction day

₹88.25

prior close

₹82.75

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.3% vs market

Pharmaceuticals peers, median of 157sector+0.0%-4.4% vs sector

On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 4.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.7

10m

+2.7

15m

+2.7

30m

+3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.4-0.1-4.3+0.0-4.4

Next day

-2.1+0.5-2.6-0.1-2.0

+0.7-0.3+1.0-0.9+1.7

+2.0-0.5+2.5-1.4+3.3

-0.3-0.8+0.5-1.6+1.3

-3.7-2.3-1.4-2.3-1.4

-3.3-2.8-0.6-2.9-0.5

15d

-2.6-4.9+2.3-3.6+1.0

-11.5-4.7-6.7-4.3-7.2

-12.7-7.7-5.0-5.6-7.1

-5.9-7.8+1.9-10.7+4.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Denis Chem Lab reported Q2 FY26 revenue from operations of Rs. 4,617.13 lakh, down about 3.4% from Rs. 4,781.76 lakh in the year-ago quarter. Profit after tax for the quarter fell sharply to Rs. 221.25 lakh vs. Rs. 353.06 lakh in Q2 FY25, a decline of roughly 37%. For the half year ended September 2025, revenue was nearly flat at Rs. 8,944.72 lakh versus Rs. 8,907.50 lakh a year ago, while H1 PAT dropped about 16% to Rs. 468.75 lakh. EBITDA margins compressed due to higher employee, depreciation, and finance costs, and operating cash flow for the half year turned negative at Rs. (83.94) lakh compared with a strong positive year-ago period. Short-term borrowings jumped sharply to Rs. 753.09 lakh from Rs. 36.73 lakh, and trade receivables ballooned to Rs. 4,209.92 lakh from Rs. 3,061.48 lakh. The auditors (Shah & Shah Associates) issued an unmodified review report, and a 15% dividend (Rs. 1.50 per share) was approved at the AGM.

Likely market impact

Higher working-capital strain, rising short-term debt, weaker margins, and a PAT decline year-on-year may pressure the stock in the near term, though the clean audit opinion and ongoing dividend provide some support.